A platform-technology company that provides devices, diagnostics, infection control and imaging for specialists treating a wide range of gastrointestinal diseases.
Medtech company EndoChoice Holdings has introduced the third-generation Fuse full spectrum endoscopy system.
On June 5, EndoChoice Holdings Inc. (NYSE:GI), completed an IPO, raising nearly $106 million on the New York Stock Exchange. River Cities Fund IV first invested in EndoChoice in 2008 and is the second-largest stakeholder in the company.
EndoChoice announced the close of a $57 million financing. Proceeds will go toward continued expansion of sales and marketing efforts of the Fuse Full Spectrum Endoscopy platform.
EndoChoice has been named as one of “Atlanta’s Best and Brightest Companies to Work For™”, a designation that hundreds of companies pursue. EndoChoice was identified as a company that delivers exceptional human resource practices as measured by the National Association for Business Resources.
New Study Published in The Lancet Oncology Shows EndoChoice Fuse System Detects Significantly More Pre-Cancerous Polyps
Fuse™ Colonoscopy dramatically outperforms standard forward-viewing colonoscopes.